CLAIMS

1. A mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131 corresponding to SEQ ID NO: 1, wherein said mutation is a substitution mutation selected from K130Y and/or I131Y, wherein the protein is an agonist of the CD200 receptor.

2. The protein as defined in claim 1, which comprises one or more additional mutations, ~~such as those~~ wherein the one or more additional mutations is selected from G129I, F128R, and N81K.

3. The protein as defined in claim 1 or claim 2, which comprises an amino acid sequence with at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

~~3~~4. The protein as defined in claim 1, comprising the sequence of SEQ ID NO: 12 or SEQ ID NO: 13.

~~4~~5. The protein as defined in any one of claims 1 to ~~3~~4, which comprises the extracellular domain (ECD) of said protein having at least 90% sequence identity with an amino acid sequence of SEQ ID NO: 2.

~~5~~6. The protein as defined in any of claims 1 to ~~4~~5, comprising the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

7. The protein as defined in any one of claims 1 to 6, wherein the mutated CD200 protein has a higher affinity for the CD200 receptor compared to a wild type or non-mutated CD200 protein.

~~6~~8. A fusion protein comprising the protein as defined in any of claims 1 to ~~5~~7, fused to a non-CD200 protein encoding portion via an optional linker portion.

~~7~~9. The protein as defined in claim ~~6~~8, wherein said linker portion is a peptide comprising between 1 and 15 amino acids.

~~8~~10. The protein as defined in claim ~~6~~8 or claim ~~7~~9, wherein said non-CD200 protein encoding portion is an antibody or fragment thereof.

~~9~~11. The protein as defined in any of claims ~~6~~8 to ~~8~~10, wherein said non-CD200 protein encoding portion is an Fc fragment.

~~10~~12. The protein as defined in any of claims ~~6~~8 to ~~9~~11, comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

~~11~~13. A polynucleotide encoding a protein as defined in any of claims 1 to ~~10~~12.

~~12~~14. A pharmaceutical composition comprising the protein as defined in any of claims 1 to ~~10~~12.

~~13~~15. Use of the protein as defined in any of claims 1 to ~~10~~12, or the composition as defined in claim ~~12~~14 in the manufacture of a medicament for the treatment of autoimmune disease.